Hu Xueda, Wan Shengqing, Ou Ying, Zhou Boping, Zhu Jialou, Yi Xin, Guan Yanfang, Jia Wenlong, Liu Xing, Wang Qiudao, Qi Yao, Yuan Qing, Huang Wanqiu, Liao Weijia, Wang Yun, Zhang Qinghua, Xiao Huasheng, Chen Xinchun, Huang Jian
Shenzhen Key Laboratory of Infection and Immunity, Shenzhen Third People's Hospital, Guangdong Medical College, Shenzhen 518112, China; BGI-Shenzhen, Shenzhen 518083, China.
BGI-Shenzhen, Shenzhen 518083, China.
Cancer Lett. 2015 Feb 28;357(2):510-9. doi: 10.1016/j.canlet.2014.12.006. Epub 2014 Dec 8.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, although the treatment of this disease has changed little in recent decades because most of the genetic events that initiate this disease remain unknown. To better understand HCC pathogenesis at the molecular level and to uncover novel tumor-initiating events, we integrated RNA-seq and DNA-seq data derived from two pairs of HCC tissues. We found that BLCAP is novel editing gene in HCC and has over-editing expression in 40.1% HCCs compared to adjacent liver tissues. We then used RNA interference and gene transfection to assess the roles of BLCAP RNA editing in tumor proliferation. Our results showed that compared to the wild-type BLCAP gene, the RNA-edited BLCAP gene may stably promote cell proliferation (including cell growth, colony formation in vitro, and tumorigenicity in vivo) by enhancing the phosphorylation of AKT, mTOR, and MDM2 and inhibiting the phosphorylation of TP53. Our current results suggest that the RNA over-editing of BLCAP gene may serve as a novel potential driver in advanced HCC through activating AKT/mTOR signal pathway.
肝细胞癌(HCC)是全球最常见的癌症之一,尽管近几十年来这种疾病的治疗方法变化不大,因为引发这种疾病的大多数基因事件仍然未知。为了在分子水平上更好地理解HCC的发病机制并发现新的肿瘤起始事件,我们整合了来自两对HCC组织的RNA测序和DNA测序数据。我们发现BLCAP是HCC中的一个新的编辑基因,与相邻肝组织相比,在40.1%的HCC中存在过编辑表达。然后我们使用RNA干扰和基因转染来评估BLCAP RNA编辑在肿瘤增殖中的作用。我们的结果表明,与野生型BLCAP基因相比,RNA编辑的BLCAP基因可能通过增强AKT、mTOR和MDM2的磷酸化并抑制TP53的磷酸化来稳定地促进细胞增殖(包括细胞生长、体外集落形成和体内致瘤性)。我们目前的结果表明,BLCAP基因的RNA过编辑可能通过激活AKT/mTOR信号通路成为晚期HCC的一种新的潜在驱动因素。